Myomycinis an unusual pseudodisaccharide antibiotic with a /3-lysyl oligopeptide ester side chain that has structural similarities with kasugamycin, streptomycin and streptothricin. Weshowthat the modeof action of myomycinin vivo and in vitro closely resembles that of streptomycin; in addition, spontaneous myomycin-resistant mutants of Escherichia coli are essentially indistinguishable from streptomycin-resistant mutants at the rRNAand r-protein level. Myomycin is not a substrate for the known streptomycin-modifying enzymes and could be useful in the characterization of natural streptomycin-resistant isolates and in counterselecting against the presence of streptomycin-modifying enzymes. The relationship between structure and inhibition of protein synthesis has been examined for a series of derivatives of myomycin.
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The aminoglycoside-aminocyclitol antibiotics (AGACs) are a large group of important antimicrobial agents^. The AGACsare produced by a variety of bacterial genera, including Actinomyces, Streptomyces and Bacillus sp. ; the primary mode of antimicrobial action of AGACshas been identified as inhibition of protein synthesis by direct interaction with the bacterial ribosome. The majority of membersof this group also induce mistranslation of the genetic code and associated phenotypic suppression of bacterial mutants2). The most widely used AGACs, clinically, are those of the 2-deoxystreptamine type. Of the other structurally related but less well knownmembers of the group, several have been useful in molecular studies of antibiotic mechanismof action, antibiotic resistance and target structure-activity analyses, although not employed therapeutically. AGACshave been particularly useful in analysing the mechanism of translation and the details of ribosome function both directly and indirectly {e.g. resistant mutants)3).
Myomycin, a broad spectrum antibiotic, was first described in 19734). It is produced by a member of the Nocardia genus as a mixture of three strongly-basic carbohydrate components. The major component, myomycinB, has been analyzed chemically in some detail and the structure (Fig. 1 ) was revised in 19815»6). Myomycin is of interest since it contains the carbohydrate myoinositol; only one other AGAC, kasugamycin, possesses a similar moiety. Myomycinhas a weak but broad spectrum of antibacterial activity; presumably for this reason the compound was not developed further as a clinical agent. Wewere interested in studying the mode of action and resistance to myomycin since it is an unusual memberof the Table 7 .
AGACclass with (apparent) chemical similarities to kasugamycin (inositol moiety), streptomycin (carbamoyl functions), and streptothricin D (/3-lysine peptide moiety). We found to our surprise, that myomycinresembles streptomycin closely in its biological activity and in its resistance mechanismat the ribosome level; the similarity in modeof action between streptomycin and myomycinimplies that they have commonstructural and conformational aspects that allow interaction with the same site on the 30S subunit of the ribosome. Like streptomycin70, myomycinhas been shownto exert characteristic physiological changes (bleaching) in light-grown cells of Euglena8\
Materials and Methods
The bacterial strains were standard Escherichia coli isolates and derived mutants (using CA274as parent) taken from our laboratory collection. Spontaneous resistant mutants were obtained at a frequency of~10~8. Conjugation and transductional analysis were performed by the usual methods95. Methodology for the analysis of the modeof action of myomycinin vivo and in vitro has been described10). Myomycin was kindly provided by Parke-Davis, Ann Arbor, Michigan, and by Lederle Laboratories, Pearl River, N.Y., U.S.A.
Results
Antibacterial Action of Myomycin Myomycinadded at inhibitory concentrations (> 100^g/ml) to growing cultures of E. coli, rapidly arrested cell growth with concomitant decrease in viability. Whenmacromolecular syntheses were examined in minimal medium, it was found that radioactive amino acid incorporation into protein was immediately inhibited by the drug (Fig. 2) but that incorporation of [uC]uracil into nucleic acid continued unabated for at least one doubling time (Fig. 3) . Myomycin thus shows the characteristic behaviour of a protein synthesis inhibitor^. Among E. coli strains tested for their response to myomycinwere several streptomycinresistant and streptomycin-dependent mutants ; these were found to be generally resistant or dependent on myomycin. In addition, myomycincould replace streptomycin, paromomycin, or alcohol effectively in supporting the growth of streptomycin-dependent mutants. This suggested that myomycin had a modeof action similar to that of streptomycin and in confirmation of this, we found that myomycincould suppress phenotypically the same range of nonsense and missense mutants of E. coli that weresusceptible to streptomycin10.
Action of Myomycinand Cell-free Translations The results described above strongly suggested that myomycinwas a functional analogue of streptomycin at the ribosome level. Whenadded to poly U-directed cell-free translation systems, myomycin was found to inhibit [14C]phenylalanine incorporation (Tables 1 and 2 ) or R17-directed incorporation (Table 3) and to stimulate the incorporation of [14C]leucine and other "wrong" amino acids into protein (mistranslation) ( Table 4 ). These effects were not seen with cell-free systems derived from myomycin-resistant mutants or most streptomycinresistant mutants tested, and were associated with ribosomes and not supernatant fractions.
Additional studies (Table 5 ) demonstrated that myomycin-resistance was associated with the 30S ribosomal subunit.
More detailed analysis with bacteriophage R1 7 RNA-primed translation showedthat myomycinwas a potent inhibitor of this system (Tables 3 and 5 ) and that the antibiotic inhibited R17 RNA-directed binding of fMet-tRNA to 30S ribosomes12) ( Table 6 ). We conclude that myomycin is essentially identical to streptomycin in its inhibitory action on bacterial ribosome function. This conclusion was confirmed and extended by the following genetic studies. Incubation mixtures contained 0.50 OD260of 70S ribosomes; ribosomes were heat activated by prior incubation at 40°C for 20 minutes: total volume 0.1 ml.
MyomycinResistance Streptomycin-resistant mutants (rps L) were almost invariably resistant to high concentrations of myomycin. Amonga collection of some 100 independent strR mutants of a single E. coli parent (CA274), all but one were highly resistant to myomycin; the exception, mutant 274-22, was only partially sensitive to myomycin. Independently-isolated, spontaneous myomycin-resistant mutants of E. coli were all found to be resistant to streptomycin and the myomycin-resistancemutations mapped to the rps L allele in PI co-transduction and conjugation studies (50% linked to aro E; 10% 50S subunits from a sensitive strain were supplied to give total 70S cone per incubation at 0.50 OD260 ; ribosomes were heat activated ; mixtures incubated 30 minutes at 37°C; misreading is defined as the incorporation of labeled serine, tyrosine and isoleucine with poly U as exogenous messenger. Incubationmixtures contained 0.50 OD260 of 70S ribosomes in a total volume of 0.1 ml; poly U incubations for 10 minutes and R17 for 30 minutes at 37°C; ribosomes were heat activated by prior incubation at 40°C for 20 minutes. S refers to subunits isolated from CA274; R to subunits from CA274-14. Cell-free extracts were prepared from either E. coli or S. cerevisiae and assayed for poly U-directed polyphenylalanine synthesis as described21>22). Extracts were incubated for 60 minutes at 30°C in the presence or absence of the various drugs using drug concentrations of 5^g/ml or 20 /*g/ml for E. bition by either drug over a range of concentrations. Weconclude that single amino acid changes in ribosomal protein S12 are responsible for resistance to myomycin(as with streptomycin); no other mutation to resistance to myomycin(other than low level transport defects) has been found. Furthermore, about 10 % of all myomycin-resistant mutants were found to be growth dependent on the presence of the drug (or streptomycin or alcohol); all streptomycin-dependent mutants of E. coli tested were found to grow equally well on myomycin. Recently, Montandon et al.w and his co-workers have demonstrated that a C912 to U base change in E. coli 16S rRNAleads to a high level streptomycin-resistance phenotype13). Such mutants were crossresistant to myomycin (results not shown) which confirms the identity of the binding site for the two antibiotics on the bacterial ribosome. Manyclinical bacterial isolates are resistant to streptomycin as a result of plasmid-encoded 0-phosphorylation or O-adenylylationu) ; as might be expected on structural grounds, none of these resistant strains were resistant to myomycin; myomycin was not enzymatically modified by extracts of the R-plasmid containing strains tested. It should be noted that acetylation of streptothricin has been reported recently15) ; the modification does not take place on the moiety commonto myomycin and strains carrying this determinant are sensitive to myomycin. To date, no plasmid-mediated resistance to myomycinhas been detected by screening more than one hundred clinical isolates of bacteria. The organism that produces myomycin(a Nocardia sp. ) has not yet been examined for enzymatic modification of the drug. Streptomycin-producing organisms (Streptomyces griseus, $. bikiniensis, S. glaucescens) which are known to possess streptomycin-phosphorylating enzymes16) are sensitive to myomycinand ribosomes from other aminoglycoside-producing organisms resistant to their endogenous antibiotic (kanamycin, gentamicin, etc.) remained sensitive to myomycin (E.
Cundliffe ; personal communication).
Structure-activity Relationships
Borders et al.5\ and McGahrenet al.6) have isolated several compounds structurally related to myomycin from the producing Nocardia sp., two of which had potent antimicrobial activity. The active molecules possessed the same basic pseudodisaccharide structure but differed in the length of the /3-lysine chain (2~5 residues) (Fig. 1) . These compounds all inhibited poly U-directed phenylalanine synthesis on E. coli ribosomes and all were, at the same concentrations, slightly more potent than streptomycin. This could indicate that basicity (number of amino groups) is not, alone, a determinant of activity in these compounds; the naturally-occurring /3-lysine oligomers alone were devoid of antibacterial or in vitro activity ( Table 7) . As might be expected, none of these compounds(including myomycinand streptomycin) had any activity against polypeptide synthesis on yeast ribosomes, even at concentrations of 100 y^g/ml.
Discussion
Wedescribe studies on the modeof action and mechanismof resistance to the antibiotic myomycin. Although myomycin bears little obvious structural relationship to streptomycin, it has a mode of action and an altered-target-site mechanismof resistance which is essentially identical to that of streptomycin. The two antibiotics must bind to the same site on the SOSribosomal subunit as defined by alterations in the amino acid sequence of the SOS ribosomal protein S1217~19) shown to involve an interaction with 16S ribosomal RNA. Different interactions arising from the dissimilar structural aspects of the two drugs could be probed, presumably, by analysis of second site revertants of drug-dependent strains. In addition, single nucleotide changes in 16S rRNAled to resistance to both drugs. Myomycinand streptomycin, thus, represent an example of two structurally different ligands binding to the same biological receptor site. Not surprisingly, E. coli mutants resistant to streptomycin and other aminoglycosides resulting from defects in transport or energy functions20) were also resistant to myomycin. Thus far no plasmid-encoded modification of myomycin has been detected in screening of a large number of bacterial clinical isolates ; it should be noted that myomycinhas never been employed as an antibiotic product for human or animal use. It will be interesting to see if the myomycin-producing Nocardia (comparatively few aminoglycosides have been obtained from Nocardia sp.) possesses an enzymatic modification of the drug or a target-mediated mechanismfor myomycin-resistance. Streptomycin-producing organisms knownto possess ribosomes sensitive to streptomycin but with enzymatic mechanismscapable of mediating streptomycin-resistance, were found to be sensitive to myomycin. Myomycinprovides, therefore, a convenient means for screening resistant bacterial isolates to distinguish between ribosomal alterations and the enzymatic inactivation of streptomycin.
Because of their structural differences, myomycinand streptomycin could be useful in analyses of ribosome structure and conformation at the molecular level and even more valuable if three dimensional structures of the two antibiotics could be compared, particularly in relationship to their 16S RNAbinding site (the C912 region)13»19). Moreover, if might be instructive to use myomycinas a means of analyzing the basis of the toxic side effects of streptomycin. Since the two drugs are different in structure but identical in modeof ribosomal interaction, one could ask if the side effects of streptomycin were related uniquely to its interaction with ribosomes by carrying out a comparative toxicity study with streptomycin and myomycin. It is worth noting that myomycinand streptomycin have one other feature in common;both antibiotics are knownto cause "bleaching" of chloroplasts in blue-green algae7>8\ Finally, one might also imagine the possibility of myomycin-streptomycin hybrids that are refractory to the enzymatic modifications responsible for the existing widespread streptomycin-resistance.
